In short
This article discusses a Phase 2 clinical trial investigating the continued use of Parsaclisib Hydrochloride, also known as INCB050465, for patients with advanced malignancies and immune-related diseases. The study aims to provide ongoing treatment for participants who have previously been enrolled in studies involving Parsaclisib, either as a standalone therapy or in combination with other drugs. The trial focuses on evaluating the safety and effectiveness of this treatment approach for patients who have shown clinical benefits from previous Parsaclisib studies.
At a glance
- Study Type
- Phase 2, Open-Label, Multicenter, Rollover Study
- Main Objective
- Provide continued treatment and evaluate safety of Parsaclisib
- Target Conditions
- Advanced malignancies and IAI diseases
- Primary Medication
- Parsaclisib Hydrochloride (INCB050465)
- Combination Therapies
- Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab
- Administration Route
- Oral use
- Maximum Daily Dose
- 20 mg
- Maximum Treatment Period
- 23 months
- Primary Endpoint
- Assessment of AEs and SAEs
- Key Eligibility Criteria
- Currently enrolled in Parsaclisib study, tolerating treatment, receiving clinical benefit
What is Parsaclisib?
Parsaclisib Hydrochloride, also known by its research code INCB050465, is a promising new medication being studied for the treatment of various advanced malignancies (cancers) and autoimmune diseases. It is currently being developed by Incyte Corporation and is in the clinical trial phase, which means it's still being tested to ensure its safety and effectiveness before it becomes widely available to patients.
Medical Conditions Treated
Parsaclisib is being investigated for its potential to treat two main categories of diseases:
- Advanced malignancies: These are cancers that have progressed to an advanced stage.
- IAI diseases: This likely refers to inflammatory and autoimmune diseases. One specific condition mentioned in the trial information is autoimmune hemolytic anemia, a disorder where the immune system mistakenly destroys red blood cells.
How Parsaclisib Works
While the exact mechanism of action is not detailed in the provided information, Parsaclisib is likely a targeted therapy. Many new cancer and autoimmune disease treatments work by targeting specific molecules involved in the disease process. This targeted approach often results in more effective treatment with fewer side effects compared to traditional therapies.
Administration and Dosage
Parsaclisib is administered as a tablet for oral use. The maximum daily dose being studied is 20 mg, with a maximum total dose of 13,990 mg over a treatment period of up to 23 months. However, it's important to note that these dosages are part of the clinical trial and may not reflect the final recommended dosage if the drug is approved for general use.
Current Clinical Trials
Parsaclisib is currently being studied in a Phase 2, open-label, multicenter rollover study. This study aims to provide continued treatment for participants who were previously enrolled in other studies of Parsaclisib and are experiencing clinical benefits. The main objective of this study is to continue evaluating the safety of Parsaclisib when used alone or in combination with other medications such as itacitinib, ruxolitinib, ibrutinib, or tafasitamab.
Eligibility for Treatment
To be eligible for the current clinical trial, patients must meet several criteria, including:
- Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of Parsaclisib
- Tolerating the treatment well
- Experiencing clinical benefit from the treatment
- Having at least stable disease, as determined by the investigator
- Demonstrating compliance with the study requirements
- Willingness to comply with scheduled visits and treatment plans
Safety Monitoring
The primary focus of the current clinical trial is to assess the safety of Parsaclisib. Researchers are closely monitoring for adverse events (AEs) and serious adverse events (SAEs) in participants receiving Parsaclisib, either alone or in combination with other medications. This ongoing safety evaluation is crucial for determining the long-term safety profile of the drug and identifying any potential risks or side effects.
It's important to remember that Parsaclisib is still an investigational drug. While it shows promise, more research is needed to fully understand its effectiveness and safety profile. Patients interested in this treatment should discuss it with their healthcare provider to determine if participating in a clinical trial might be appropriate for their specific situation.